Tumefactive demyelination following treatment for relapsing multiple sclerosis with alemtuzumab

Joshua Barton¹, Todd A Hardy¹, Sean Riminton¹+4

• ¹From the Brain & Mind Centre (J.B., T.A.H., S.W.R., M.H.B.), University of Sydney; Neuroimmunology Clinic (T.A.H., S.R., S.W.R.), Concord Repatriation General Hospital, Sydney; Sydney Neuroimaging Analysis Centre (Y.B., M.H.B.); St Vincent's Hospital (Y.B.), Sydney, Australia; and Addenbrookes Hospital (A.C.), University of Cambridge, UK.+1